Acurx Pharmaceuticals LLC (ACXP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Acurx Pharmaceuticals LLC (ACXP) has a cash flow conversion efficiency ratio of -0.001x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.88 Million) by net assets ($3.64 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Acurx Pharmaceuticals LLC - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Acurx Pharmaceuticals LLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Acurx Pharmaceuticals LLC (ACXP) financial obligations for a breakdown of total debt and financial obligations.
Acurx Pharmaceuticals LLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acurx Pharmaceuticals LLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Multi-Usage Holdings Bhd
KLSE:9539
|
-0.001x |
|
Seraphim Space Investment Trust PLC
LSE:SSIT
|
-0.006x |
|
D.T.C. Industries Public Company Limited
BK:DTCI
|
0.014x |
|
Alfa Financial Software Holdings PLC
LSE:ALFA
|
0.350x |
|
NGX Ltd
AU:NGX
|
-0.125x |
|
DTCOM - Direct to Company S.A
SA:DTCY3
|
-3.060x |
|
Danish Aerospace Company A/S
CO:DAC
|
-0.231x |
|
Tedea Technological Development and Automation Ltd
TA:TEDE
|
-0.890x |
Annual Cash Flow Conversion Efficiency for Acurx Pharmaceuticals LLC (2019–2024)
The table below shows the annual cash flow conversion efficiency of Acurx Pharmaceuticals LLC from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see Acurx Pharmaceuticals LLC stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $615.12K | $-10.38 Million | -16.880x | -703.75% |
| 2023-12-31 | $4.67 Million | $-9.80 Million | -2.100x | -103.69% |
| 2022-12-31 | $7.32 Million | $-7.54 Million | -1.031x | -155.22% |
| 2021-12-31 | $12.41 Million | $-5.01 Million | -0.404x | +67.44% |
| 2020-12-31 | $2.70 Million | $-3.35 Million | -1.241x | +74.48% |
| 2019-12-31 | $819.85K | $-3.99 Million | -4.861x | -- |
About Acurx Pharmaceuticals LLC
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potenti… Read more